In re AndroGel Antitrust Litigation (II), 09-md-2084 (N.D. Ga.)

In the Androgel litigation, Faruqi & Faruqi, LLP represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott’s branded testosterone drug, AndroGel.  The case alleges that Abbott’s predecessor filed baseless patent litigation and entered a series of horizontal market allocation agreements with generic manufacturers Watson and Par/Paddock (also defendants in the case) to delay generic competition in violation of §§ 1 and 2 of the Sherman Act.  The class asserts that, as a result of the delay in generic competition, direct purchasers were overcharged by hundreds of millions of dollars.